CliffBio
small molecule

XIMINO

MINOCYCLINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyJOURNEY MEDICAL CORP

Drug detail

Brand nameXIMINO
Active ingredientMINOCYCLINE HYDROCHLORIDE
StrengthEQ 112.5MG BASE
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2012
Marketing statusDISCN

More from JOURNEY MEDICAL CORP

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

XIMINO patent cliff — loss of exclusivity — | CliffBio